Droperidol Dosing for Cannabinoid Hyperemesis Syndrome
For an adult with acute cannabinoid hyperemesis syndrome and no known QT prolongation or significant cardiac disease, administer droperidol 1.25 mg intravenously as the initial dose, which can be repeated if needed, with a typical total dose range of 1.25-2.5 mg IV.
Rationale for This Recommendation
The most recent high-quality evidence specifically for CHS demonstrates that droperidol at a median dose of 1.25 mg IV significantly reduces length of stay (409 vs 641 minutes), decreases total medication use, and reduces opioid requirements compared to standard antiemetic therapy 1. This 2025 retrospective study of 211 encounters showed only 2 mild adverse reactions with droperidol use, supporting its safety profile at this dose.
Dosing Algorithm
Initial Dose
- Start with 1.25 mg IV - This is the most frequently used and studied dose in CHS patients 2, 3
- Onset of action: 3-10 minutes 4
- Duration of effect: 2-4 hours 4
Dose Adjustment
- If inadequate response after 30 minutes, may repeat 1.25 mg IV
- Total dose range: 1.25-2.5 mg IV for endoscopic sedation and CHS management 5, 4, 5, 4
- Higher doses up to 5 mg have been used for acute agitation in emergency settings 6, but lower doses are preferred for CHS to minimize cardiac risk
For Acute Agitation Context (Different from CHS)
- Emergency department agitation studies used 5 mg IM or IV 6
- Weight-based dosing was studied but 5 mg fixed dose showed superiority over lorazepam 6
Critical Safety Considerations
Mandatory Pre-Treatment Assessment
The FDA black box warning requires specific precautions 7:
- Obtain 12-lead ECG before administration to measure QTc interval
- Do NOT administer if QTc >440 msec (males) or >450 msec (females) 5, 4, 5, 4, 7
- Continue ECG monitoring for 2-3 hours post-treatment 7
Contraindications
Droperidol is absolutely contraindicated in 7:
- Known or suspected QT prolongation
- Congenital long QT syndrome
High-Risk Situations Requiring Extreme Caution
Avoid or use with extreme caution if patient has 5, 4, 5, 4, 7:
- Congestive heart failure
- Bradycardia (<50 bpm)
- Cardiac hypertrophy
- Hypokalemia or hypomagnesemia
- Diuretic use
- Age ≥65 years
- Alcohol abuse (note the irony: CHS patients may have this risk factor)
- Concurrent use of Class I/III antiarrhythmics or other QT-prolonging drugs
Clinical Effectiveness Data
Symptom improvement is rapid and substantial 3:
- Nausea/vomiting VAS scores: 8.3 at baseline → 3.1 at 30 minutes → 1.4 at 120 minutes
- Abdominal pain VAS scores: 7.8 at baseline → 3.6 at 30 minutes → 1.7 at 120 minutes
- ED return rate within 7 days: 12.9%
The 2019 Australian study showed droperidol reduced median length of stay from 13.9 hours to 6.7 hours (p=0.014) and required half the number of other antiemetics compared to standard treatment 2.
Important Caveats
The FDA Black Box Warning Context
While the FDA issued a black box warning in 2001 based on high-dose use (25 mg) in psychiatric patients 4, large safety reviews are reassuring at lower doses:
- 2,468 ED patients (1,357 for agitation) had only 6 adverse events, none were dysrhythmias, and none occurred in patients without serious comorbidities 6
- An estimated 12,000 patients treated for agitation had no dysrhythmic events 6
- Reviews concluded that while droperidol can prolong QT interval, convincing evidence for severe cardiac events at therapeutic doses is lacking 6
Dose Reduction Needed
- Reduce dose in patients with renal or liver disease 5
Common Side Effects
- Hypotension is the most common complication (24% in one series) 5, 4, 5, 4
- Extrapyramidal symptoms/dystonia (rare at low doses, one case reported in major ED study) 6
- Have fluids and countermeasures for hypotension readily available 7
Combination Therapy Option
Recent prospective data suggests combining droperidol with diphenhydramine 50 mg IV may enhance effectiveness 3. This combination showed significant symptom improvement with the same safety profile.
Why Droperidol Over Other Antiemetics
Traditional antiemetics (ondansetron, metoclopramide, promethazine) are often ineffective in CHS 8, 9, 10. Droperidol's dopamine antagonism appears particularly effective for CHS-related nausea and vomiting, similar to haloperidol (which guidelines also support at 5 mg IM) 8, 9, 10. However, droperidol has faster onset and may be preferred when rapid sedation is required 6.